Prostate Diagnostic Leverage Precision Biopsy’s spectroscopic imaging platform as a complementary diagnostic tool to reduce sampling errors in prostate biopsies, presenting an opportunity to partner with urology clinics and pathology networks seeking improved accuracy and cost savings.

Clinical Collaboration Target academic and medical centers that collaborate with University of Colorado researchers and Allied Minds to explore joint trials or pilot programs, offering access to cutting-edge imaging technology and potential co-authored publications.

Early Stage Growth With under $1M revenue and substantial funding, pursue strategic partnerships with larger diagnostic firms or contract research organizations to scale deployment, manufacturing, and regulatory clearance for broader market adoption.

Strategic Partnerships Position as a high-tech, academically driven solution in the medical device space to attract alliances with sequencing, pathology informatics vendors, or hospital system integrators aiming to augment existing prostate cancer workflows.

Global Expansion Readiness Given backing by Allied Minds and a global investor footprint, prepare regional market entry plans focusing on regulatory pathways, reimbursement incentives, and hospital procurement channels to accelerate international adoption.